Solifenacin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Solifenacin
- Solifenacin: From Overactive Bladder to Polycystic Kidney Disease 3 (with or without Polycystic Liver Disease)
Solifenacin: From Overactive Bladder to Polycystic Kidney Disease 3 (with or without Polycystic Liver Disease)
One-Sentence Summary
Solifenacin is a muscarinic receptor antagonist originally used to treat overactive bladder. The TxGNN model predicts it may be effective for polycystic kidney disease 3 with or without polycystic liver disease, but no clinical trials and no publications currently support this direction. The prediction rests on model output alone, and no pharmacological rationale is evident.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Overactive bladder (the Singapore licence records contain no indication text, so this comes from the knowledge-graph indication data) |
| Predicted New Indication | Polycystic kidney disease 3 with or without polycystic liver disease |
| TxGNN Prediction Score | 97.13% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 7 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Solifenacin is a selective M3 muscarinic receptor antagonist. It acts on the smooth muscle of the bladder detrusor. By reducing involuntary bladder contractions, it relieves urgency, frequency and urge incontinence. Detailed mechanism-of-action data were not available in the data compiled for this report, so this description relies on the known pharmacology of the drug class.
The mechanistic link is weak. Polycystic kidney disease 3 is a genetic, ciliopathy-type disorder. Cyst formation in these diseases is driven by signalling pathways unrelated to muscarinic receptor blockade. The high TxGNN score most likely reflects proximity in the knowledge graph, for example shared renal or urinary phenotype nodes, rather than a true pharmacological connection.
At best, solifenacin might ease secondary bladder symptoms in patients with renal disease. There is no evidence that it modifies the underlying cystic pathology.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
Seven single-ingredient oral film-coated tablet licences are currently valid. None are cancelled. The licence records contain no approved-indication text. The five below are a selection.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN13702P | Vesicare Tablet 5mg | Film-coated tablet | — |
| SIN13703P | Vesicare Tablet 10mg | Film-coated tablet | — |
| SIN15331P | Bladiton Film Coated Tablets 5mg | Film-coated tablet | — |
| SIN16334P | Synerrv Solifenacin Succinate Film-Coated Tablets 10mg | Film-coated tablet | — |
| SIN16679P | Dalisoon F.C. Tablets 5mg | Film-coated tablet | — |
Safety Considerations
Please refer to the package insert for warnings and contraindications.
- Contraindication-related conditions (knowledge graph, not label text): long QT syndrome, familial long QT syndrome, torsades de pointes, liver failure, liver disease, gallbladder disease, angle-closure (closed-angle) glaucoma, and bladder neck obstruction.
- Drug interactions: The interaction query returned 100 interactions in total. The 20 reviewed include:
- Major: potassium citrate, clarithromycin, dolasetron.
- Moderate: other anticholinergic or antispasmodic agents (atropine, hyoscyamine, glycopyrronium, clidinium, dicyclomine, trospium), loperamide, morphine, aprepitant, dexamethasone, famotidine, cimetidine, palonosetron, eluxadoline, and several laxatives or bowel-preparation agents.
- Relevance to this prediction: Patients with kidney or liver disease may fall into the liver-disease contraindication group above. Anticholinergic effects would also add to those of other anticholinergic drugs.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a high model score but no supporting trials or literature, and no plausible pharmacological link between muscarinic antagonism and the genetic cystic pathology. The evidence is model-only (L5).
For reference: Among the other predicted indications, "low compliance bladder" (rank 7, score 95.37%) is the only one with supporting literature. It has 11 publications, including a paediatric neurogenic detrusor overactivity study (PMID 32007426) and several trospium or mirabegron combination studies. This evidence is indirect, and the indication is closer to an extension of the approved use than true repurposing. It could be pursued as a separate research question.
To proceed, the following is needed:
- Mechanism-of-action data for solifenacin
- Package insert warnings and contraindications from the HSA website
- A mechanistic or preclinical rationale linking muscarinic antagonism to the disease
- Any registered trials or published studies in this indication before reconsidering
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.